Entries / intervention
Fezolinetant
moderate Evidence strength · Status: published · Source agreement: medium
Not medical advice
Menowise aggregates and organizes what the published literature reports, with citations. It does not diagnose, advise, or recommend treatment. Talk to a qualified clinician about your own care.
What the literature reports
Fezolinetant is a neurokinin 3 (NK3) receptor antagonist and, per The Menopause Society's 2023 Nonhormone Therapy Position Statement, a first-in-class FDA-approved medication. The statement reports it as recommended for vasomotor symptoms at Level I evidence (good and consistent scientific evidence). This entry summarizes what the literature reports for navigation and is not medical advice.
Citations
-
The Menopause Society — 2023 Nonhormone Therapy Position Statement (Menopause, 2023; PMID 37252752) — The Menopause Society (Menopause journal) (2023)
NK3 receptor antagonist; first-in-class FDA-approved; Level I evidence for VMS.
Notes
Subject is the specific drug fezolinetant. The entities registry has no dedicated id for it; it currently falls under the broad `non-hormonal-vasomotor` category entity (which lists "fezolinetant" among its aliases, kind: intervention). PROPOSED entities.yml addition: a dedicated `fezolinetant` intervention entry for cleaner navigation. Single source (2023 Nonhormone Therapy Position Statement), so confidence is medium; evidence_strength moderate reflects the statement's Level I grading, though the underlying trials/meta-analyses are not directly cited. Fezolinetant's use for vasomotor symptoms is cross-referenced on the `vasomotor-symptoms` symptom entry, kept distinct per profile (drug/intervention vs. the symptom it is studied for).
Provenance
This entry is resolved from per-source signals; the raw claims are the audit trail behind it.
- Machine record: /data/sites/fezolinetant.yml (schema-valid, verbatim)
- Signals:
sig-20260710-fezolinetant-mechanism - First recorded 2026-07-10 · last updated 2026-07-10